WO2023020563A1 - Liquid formulations comprising high concentrations humanized antibodies for treating il-6 related diseases - Google Patents
Liquid formulations comprising high concentrations humanized antibodies for treating il-6 related diseases Download PDFInfo
- Publication number
- WO2023020563A1 WO2023020563A1 PCT/CN2022/113202 CN2022113202W WO2023020563A1 WO 2023020563 A1 WO2023020563 A1 WO 2023020563A1 CN 2022113202 W CN2022113202 W CN 2022113202W WO 2023020563 A1 WO2023020563 A1 WO 2023020563A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- formulation
- arginine hydrochloride
- polysorbate
- injection
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 17
- 239000012669 liquid formulation Substances 0.000 title abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 204
- 238000009472 formulation Methods 0.000 claims abstract description 199
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 17
- 238000010254 subcutaneous injection Methods 0.000 claims abstract description 10
- 239000007929 subcutaneous injection Substances 0.000 claims abstract description 10
- 239000000872 buffer Substances 0.000 claims description 67
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical group OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 66
- 229960003589 arginine hydrochloride Drugs 0.000 claims description 66
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 58
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 58
- 229920000053 polysorbate 80 Polymers 0.000 claims description 58
- 229940068968 polysorbate 80 Drugs 0.000 claims description 58
- 239000003381 stabilizer Substances 0.000 claims description 56
- 102000005962 receptors Human genes 0.000 claims description 50
- 108020003175 receptors Proteins 0.000 claims description 50
- 229930006000 Sucrose Natural products 0.000 claims description 46
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 46
- 239000005720 sucrose Substances 0.000 claims description 46
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 43
- 229930182817 methionine Natural products 0.000 claims description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 43
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 42
- 239000008215 water for injection Substances 0.000 claims description 38
- 239000000243 solution Substances 0.000 claims description 32
- 239000004094 surface-active agent Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 21
- 239000007853 buffer solution Substances 0.000 claims description 15
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 13
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 12
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 claims description 10
- 229940074409 trehalose dihydrate Drugs 0.000 claims description 10
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 9
- 206010052015 cytokine release syndrome Diseases 0.000 claims description 9
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 9
- 229960003989 tocilizumab Drugs 0.000 claims description 7
- 208000005024 Castleman disease Diseases 0.000 claims description 6
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 6
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 6
- 208000019764 polyarticular juvenile idiopathic arthritis Diseases 0.000 claims description 6
- 230000009885 systemic effect Effects 0.000 claims description 6
- 206010043207 temporal arteritis Diseases 0.000 claims description 6
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010065159 Polychondritis Diseases 0.000 claims description 3
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 208000024340 acute graft versus host disease Diseases 0.000 claims description 3
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 3
- 238000009169 immunotherapy Methods 0.000 claims description 3
- 208000008795 neuromyelitis optica Diseases 0.000 claims description 3
- 230000000306 recurrent effect Effects 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 239000001632 sodium acetate Substances 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 2
- 208000003084 Graves Ophthalmopathy Diseases 0.000 claims 2
- 239000003708 ampul Substances 0.000 claims 1
- 229940090047 auto-injector Drugs 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 abstract description 5
- 230000002776 aggregation Effects 0.000 abstract description 3
- 238000004220 aggregation Methods 0.000 abstract description 3
- 230000015556 catabolic process Effects 0.000 abstract description 3
- 238000006731 degradation reaction Methods 0.000 abstract description 3
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 150000002411 histidines Chemical class 0.000 description 29
- 150000003839 salts Chemical class 0.000 description 26
- 229940100601 interleukin-6 Drugs 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 14
- 229960002885 histidine Drugs 0.000 description 14
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 239000004475 Arginine Substances 0.000 description 11
- 229960003121 arginine Drugs 0.000 description 11
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 11
- 239000007974 sodium acetate buffer Substances 0.000 description 11
- 102000004889 Interleukin-6 Human genes 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 8
- 230000010355 oscillation Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 6
- 238000012375 Ion exchange chromatography - high performance liquid chromatography Methods 0.000 description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 229940074410 trehalose Drugs 0.000 description 6
- 238000011094 buffer selection Methods 0.000 description 5
- 239000003638 chemical reducing agent Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 230000001133 acceleration Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000012537 formulation buffer Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 239000007991 ACES buffer Substances 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229960005337 lysine hydrochloride Drugs 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000010494 opalescence Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000006173 Good's buffer Substances 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 102100033130 T-box transcription factor T Human genes 0.000 description 1
- 101710086566 T-box transcription factor T Proteins 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000012615 aggregate Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000106 biosimilars Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000013368 capillary electrophoresis sodium dodecyl sulfate analysis Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 239000008380 degradant Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000001370 static light scattering Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Definitions
- the invention relates to liquid formulations of high concentrations of humanized anti-interleukin 6 receptor (IL-6R) antibodies for treating interleukin 6 (IL-6) related diseases.
- IL-6R humanized anti-interleukin 6 receptor
- Humanized anti-interleukin 6 receptor antibodies are useful for the treatment of rheumatoid arthritis (RA) [Josef S Smolen, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update, Ann Rheum Dis, 2014; 73 (3) : 492–509] whose mechanisms are binding soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R) and inhibiting sIL-6R and mIL-6R mediated signaling.
- RA rheumatoid arthritis
- compositions are typically administered by injection. Subcutaneous injections allow faster administration as compared with intravenous injections, and self-injection by patients. However, for antibodies that require a high dosage (e.g., over 100 mg per dose) , the antibody concentration in a subcutaneous formulation needs to be high due to the limited volume that can be administered by each subcutaneous injection, which presents formulation challenges. For example, due to high concentration, antibodies tend to aggregate which leads to reduced stability and shorter self-life. High concentration also increases the viscosity of the formulation which can make manufacturing and injection through a needle difficult. To increase shelf-life, formulations can be prepared as powders by the lyophilization. However, lyophilized powder requires reconstitution in water, making administration more complicated. Therefore, there is a need for high concentration antibody liquid formulations having long term stability and suitable for subcutaneous injection that do not require reconstitution.
- the invention provides an antibody formulation comprising a high concentration of a humanized anti-interleukin 6 receptor antibody, a buffer system, a stabilizer and a surfactant.
- the antibody formulation of present invention comprises, consists essentially of, or consists of the following ingredients:
- the pH of the antibody formulation is 5.0-7.0.
- a formulation comprises a humanized PM-1 antibody described in US2005/0142635, and optionally one or more of its variants, such as those descripted in US2016/0152714.
- the humanized anti-interleukin 6 receptor antibody is tocilizumab ( or or a biosimilar thereof, such as BAT1806 (BIIB800) ) .
- tocilizumab comprises an antibody comprising a heavy chain shown in SEQ ID NO. 1 and a light chain shown in SEQ ID NO. 2.
- SEQ ID NO. 1 is shown in Table A and SEQ ID NO. 2 is shown in Table B.
- tocilizumab comprises an antibody comprising two heavy chains, each shown in SEQ ID NO.
- tocilizumab further comprises one or more variants of the antibody comprising a heavy chain shown in SEQ ID NO. 1 and a light chain shown in SEQ ID NO. 2, such as those descripted in US2016/0152714.
- the humanized anti-interleukin 6 receptor antibody is expressed in CHO cells by genetic engineering methods and purified by a series of standard chromatographic steps. After the antibody is prepared, a pharmaceutical formulation is prepared. Each of US2005/0142635 and US2016/0152714 is hereby incorporated by reference in its entirety.
- the concentration of the humanized anti-IL-6 receptor antibody in the formulation is 130-280 mg/mL. In some embodiments, the concentration of the humanized anti-IL-6 receptor antibody in the formulation is 140-250 mg/mL. In some embodiments, the concentration of the humanized anti-IL-6 receptor antibody in the formulation is 160-200 mg/mL. In some embodiments, the concentration of the humanized anti-IL-6 receptor antibody in the formulation is 180 mg/mL.
- the stabilizer is selected from arginine or a salt thereof (e.g., arginine hydrochloride) or a combination of arginine or a salt thereof and sucrose, or trehalose (which may be added as a hydrate) .
- the stabilizer is a combination of 70-200 mM of arginine and/or a salt thereof (e.g., 14.746-42.132 mg/mL of arginine hydrochloride) and 29-87 mM (10-30 mg/mL) sucrose; or the stabilizer is a combination of 70-200 mM of arginine and/or a salt thereof (e.g., 14.746-42.132 mg/mL of arginine hydrochloride) and 26-79 mM trehalose (e.g., 10-30 mg/mL trehalose dihydrate) ; or the stabilizer is 70-200 mM of arginine and/or a salt thereof (e.g, 14.746-42.132 mg/mL arginine hydrochloride) .
- the stabilizer is a combination of 80-100 mM of arginine and/or a salt thereof (e.g., 16.853-21.066 mg/mL of arginine hydrochloride) and 44-73 mM (15-25 mg/mL) sucrose; or the stabilizer is a combination of 80-100 mM of arginine and/or a salt thereof (e.g., 16.853-21.066 mg/mL of arginine hydrochloride) and 40-66 mM trehalose (e.g., 15-25 mg/mL trehalose dihydrate) ; or the stabilizer is 110-130 mM of arginine and/or a salt thereof (e.g, 23.173-27.386 mg/mL arginine hydrochloride) .
- the stabilizer is a combination of about 90 mM of arginine and/or a salt thereof (e.g., about 18.959 mg/mL of arginine hydrochloride) and about 58.4 mM (about 20 mg/mL) sucrose; or the stabilizer is a combination of about 90 mM of arginine and/or a salt thereof (e.g., about 18.959 mg/mL of arginine hydrochloride) and about 52.9 mM trehalose (e.g., about 20 mg/mL trehalose dihydrate) ; or the stabilizer is about 120 mM of arginine and/or a salt thereof (e.g, about 25.279 mg/mL arginine hydrochloride) .
- the stabilizer further comprises methionine and/or ethylenediaminetetraacetic acid (EDTA) .
- the stabilizer further comprises methionine.
- the stabilizer further comprises EDTA.
- the stabilizer further comprises methionine and EDTA.
- the stabilizer further comprises 5-35 mM of methionine.
- the stabilizer further comprises 5-30 mM of methionine.
- the stabilizer further comprises 5 mM, 8 mM, 10 mM, 15 mM, 20 mM, 25 mM, 30 mM, or 35 mM of methionine.
- the stabilizer further comprises 5-15 mM of methionine. In some embodiments, the stabilizer further comprises 0.01-0.1 mM of EDTA. In some embodiments, the stabilizer further comprises 0.02-0.07 mM of EDTA. In some embodiments, the stabilizer further comprises 0.02 mM, 0.03 mM, 0.04 mM, 0.05 mM, 0.06 mM, or 0.07 mM of EDTA.
- the stabilizer further comprises 5 mM, 8 mM, 10 mM, 15 mM, 20 mM, 25 mM, or 30 mM of methionine and also comprises 0.02 mM, 0.03 mM, 0.04 mM, 0.05 mM, 0.06 mM, 0.07 mM, 0.08 mM, 0.09 mM, or 0.1 mM of EDTA.
- the stabilizer further comprises 5-20 mM of methionine and 0.02-0.1 mM of EDTA.
- the stabilizer further comprises 8 mM of methionine and 0.05 mM of EDTA.
- methionine as used herein includes one or more of its salts or a mixture thereof
- EDTA as used herein includes one of more of its salts or a mixture thereof.
- the stabilizer further comprises between about 5 mM and about 35 mM of methionine. In some embodiments, the stabilizer further comprises about 5 mM, about 8 mM, about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM or about 35 mM of methionine. In some embodiments, the stabilizer further comprises between about 0.01 mM and about 0.1 mM of EDTA. In some embodiments, the stabilizer further comprises between about 0.02 mM and about 0.07 mM of EDTA.
- the stabilizer further comprises about 0.02 mM, about 0.03 mM, about 0.04 mM, about 0.05 mM, about 0.06 mM, about 0.07 mM, about 0.08 mM, about 0.09 mM, or about 0.1 mM of EDTA. In some embodiments, the stabilizer further comprises between about 5 mM and about 20 mM of methionine and between about 0.02 mM and about 0.1 mM of EDTA.
- the stabilizer further comprises about 5 mM, about 8 mM, about 10 mM, about 15 mM, about 20 mM, about 25 mM, or about 30 mM of methionine and also comprises about 0.02 mM, about 0.03 mM, about 0.04 mM, about 0.05 mM, about 0.06 mM, about 0.07 mM, about 0.08 mM, about 0.09 mM, or about 0.1 mM of EDTA. In some embodiments, the stabilizer further comprises about 8 mM of methionine and about 0.05 mM of EDTA.
- the surfactant is polysorbate-80. In some embodiments, the surfactant is 0.1-0.7 mg/mL polysorbate-80. In some embodiments, the surfactant is 0.45-0.55 mg/mL polysorbate-80. In some embodiments, the surfactant is about 0.5 mg/mL polysorbate-80.
- the buffer system comprises 5-20 mM histidine and a salt thereof or 5-20 mM acetic acid and a salt thereof. In some embodiments, the buffer system comprises 8-15 mM histidine and a salt thereof or 8-15 mM acetic acid and a salt thereof. In some embodiments, the buffer system comprises 10 mM histidine and a salt thereof. In some embodiments, the buffer system comprises 10 mM acetic acid and a salt thereof.
- the pH of the antibody formulation is 5.5-6.5; or, the pH of the antibody formulation is between 5.6 and 6.4; or, the pH of the antibody formulation is between 5.8 and 6.2; or, the pH of the antibody formulation is between 5.8 and 6.0; or, the pH of the antibody formulation is between 6.0 and 6.2; or, the pH of the antibody formulation is about 5.8.
- the antibody formulation has a viscosity of from 0 to 20 cP. In some embodiments, the antibody formulation has a viscosity of from 5 cP to 15 cP. In some embodiments, the antibody formulation has a viscosity of from 8 cP to 12 cP. In some embodiments, the antibody formulation has a viscosity of about 10 cP.
- the antibody formulation comprises, consists essentially of, or consists of:
- the pH is 5.6-6.4.
- the formulation comprises, consists essentially of, or consists of:
- 40-66 mM trehalose e.g., 15-25 mg/mL trehalose dihydrate
- the pH is 5.6-6.4.
- the formulation comprises, consists essentially of, or consists of:
- the pH is 5.6-6.4.
- the antibody formulation comprises, consists essentially of, or consists of:
- the pH is 5.6-6.4.
- the antibody formulation comprises, consists essentially of, or consists of:
- the pH is 5.6-6.4.
- the antibody formulation comprises, consists essentially of, or consists of:
- the pH is 5.6-6.4.
- the antibody formulation comprises, consists essentially of, or consists of:
- the pH is 5.6-6.4.
- the antibody formulation comprises, consists essentially of, or consists of:
- the pH is 5.6-6.4.
- the formulation comprises, consists essentially of, or consists of:
- the pH is about 5.6-6.4.
- the formulation comprises, consists essentially of, or consists of:
- trehalose e.g., 20 mg/mL trehalose dihydrate
- the pH is about 5.6-6.4.
- the formulation comprises, consists essentially of, or consists of:
- the pH is about 5.6-6.4.
- the antibody formulation comprises, consists essentially of, or consists of:
- the pH is 5.6-6.4.
- the antibody formulation comprises, consists essentially of, or consists of:
- the pH is 5.6-6.4.
- the antibody formulation comprises, consists essentially of, or consists of:
- the pH is 5.6-6.4.
- the antibody formulation comprises, consists essentially of, or consists of:
- the pH is 5.6-6.4.
- the antibody formulation comprises, consists essentially of, or consists of:
- the pH is 5.6-6.4.
- the pH of the antibody formulation is about 5.8. In some embodiments, the pH of the antibody formulation is about 6.
- the viscosity of the antibody formulation is 5 cP to 15 cP. In some embodiments, the viscosity of the antibody formulation is 8 cP to 12 cP. In some embodiments, the viscosity of the antibody formulation is about 10 cP.
- a base is added to the antibody formulation for adjusting the pH.
- the base is NaOH.
- the antibody formulation is an aqueous formulation for injection.
- the formulation is suitable for subcutaneous injection.
- the invention also provides a method to prepare the antibody formulation, comprising the steps of:
- the pH of the solution prepared in the step (1) is adjusting with an aqueous sodium hydroxide solution.
- the method further comprises filtering the solution prepared in step (1) through a filter membrane into an aseptic container before adding to the antibody solution.
- the pore size of the filter membrane is 0.22 ⁇ m for filtering bacteria and fungi.
- the surfactant is added to the buffered antibody solution as a surfactant solution.
- the formulations disclosed herein are prepared without lyophilization.
- the antibody formulation is a pharmaceutical formulation for treating IL-6 related diseases.
- a method for treating IL-6 related diseases comprising administering an effective amount of a formulation described herein to a patient in need thereof.
- a formulation described herein in the preparation of a medicament for treating IL-6 related diseases In some embodiments, provided is use of a formulation described herein for treating IL-6 related diseases.
- the IL-6 related diseases include: adult rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, giant lymph node hyperplasia, cytokine storm caused by immunotherapy, cytokine release syndrome, adult Still's disease, recurrent polychondritis, type II diabetes, ankylosing spondylitis, thyroid-associated ocular diseases, cardiovascular diseases caused by rheumatoid arthritis, polymyalgia rheumatica, acute graft-versus-host disease, non-ST-segment elevation myocardial infarction, systemic lupus erythematosus, schizophrenia, uveitis, ovarian cancer, anti-neutrophil cytoplasmic antibody-associated vasculitis, neuromyelitis optica, chronic glomerulonephritis, colorectal cancer and the like.
- the IL-6 related disease is selected from rheumatoid arthritis, cytokine release syndrome, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, and giant lymph node hyperplasia.
- the effective amount of the formulation is an amount that comprises 120-300 mg per dose of the antibody once every 1 to 3 weeks.
- the antibody formulations provided by the invention comprise a high concentration of antibody with an acceptable viscosity, low turbidity and high stability suitable for administering high doses of the antibody by subcutaneous injections.
- the antibody formulations have been developed to remarkably inhibit the formation of acidic peaks, dimers, aggregates, degradants and insoluble microparticles during freezing/thawing cycles, long-term storage and temperature variation processes.
- the humanized anti-interleukin 6 receptor antibodies remain stable in the above formulations after at least 3 freeze-thaw cycles, stable at room temperature for at least 3 months. Therefore, the antibody formulations of the present invention can be used for stably storing the humanized anti-interleukin 6 receptor antibody for treating IL-6-related diseases by subcutaneous injections of the antibody in high doses required for treatment.
- the present invention provides antibody formulations by selecting buffer solutions and stabilizers, to enhance the stability of the high concentration humanized anti-interleukin 6 receptor antibody formulation, and prevent monoclonal antibody aggregation, degradation and acidic isomer increase, while having low turbidity and viscosity acceptable for subcutaneous injection.
- compositions or methods are intended to mean that the compositions or methods, etc., include the recited elements, but do not exclude others.
- Consisting essentially of when used to define compositions or methods, shall mean excluding other elements of any essential significance to the combination for the intended use, but not excluding elements that do not materially affect the characteristic (s) of the compositions or methods.
- Consisting of shall mean excluding elements not specifically recited. Embodiments defined by each of these transition terms are within the scope of this invention.
- Stability refers to the situation that in a liquid formulation comprising an antibody, the antibody does not, or only rarely, aggregate, degrade, or fragment under given production, formulation, transportation, and/or storage conditions. “Stable” formulations maintain biological activity under given production, formulation, transportation and/or storage conditions. The stability of the antibody, can be assessed by measuring the degree of aggregation, degradation or fragmentation and the like of the formulation by techniques such as SEC-HPLC, IEC-HPLC, CE-SDS, etc. In some embodiments, the main antibody peak in a stable formulation does not decrease more than 5 %after storing at room temperature for at least 3 months.
- a buffer or buffer system is included in a formulation
- the buffer is included in the formulation and the buffer system is formed in the formulation by the buffer.
- a buffer is typically a combination of a weak acid or a weak base and its salt.
- a histidine buffer also called a histidine salt buffer
- an acetate buffer is typically formed by acetic acid and one or more of its salts, such as sodium acetate.
- the molar concentration of the buffer includes both the free acid/base and the salts.
- the concentration of the monoclonal antibody in the antibody formulation is about 120-300 mg/mL. In some embodiments, the concentration of the monoclonal antibody in the antibody formulation is about 130-280 mg/mL. In some embodiments, the concentration of the monoclonal antibody in the antibody formulation is about 140-250 mg/mL. In some embodiments, the concentration of the monoclonal antibody in the antibody formulation is about 160-200 mg/mL. In some embodiments, the concentration of the monoclonal antibody in the antibody formulation is about 180 mg/mL.
- the buffer system is selected from histidine (His) buffer, citrate (CB) buffer, sodium acetate (NaAC) buffer, and succinic acid (Sua) buffer. In some embodiments, the buffer system is histidine buffer. In some embodiments, buffer system is sodium acetate buffer.
- the stabilizer comprises arginine hydrochloride, proline, lysine hydrochloride, glycine, histidine, or sodium glutamate. In some embodiments, the stabilizer comprises methionine and/or EDTA. The addition of the stabilizers further decreases the viscosity of the formulation. In some embodiments, the stabilizer is arginine hydrochloride.
- the surfactant is polysorbate-80.
- the formulation consists essentially of: about 180 mg/mL humanized anti-IL-6 receptor antibody, about 10 mM histidine salt buffer, about 0.5 mg/mL polysorbate-80, about 90 mM arginine hydrochloride, about 20 mg/mL sucrose, water for injection, with pH 5.8-6.0.
- the formulation consists essentially of: about 180 mg/mL humanized anti-IL-6 receptor antibody, about 10 mM sodium acetate buffer solution, about 0.5 mg/mL polysorbate-80, about 90 mM arginine hydrochloride, about 20 mg/mL trehalose dihydrate, water for injection, with pH 5.8-6.0.
- the formulation consists essentially of: about 180 mg/mL humanized anti-IL-6 receptor antibody, about 10 mM sodium acetate buffer solution, about 0.5 mg/mL polysorbate-80, about 120 mM arginine hydrochloride, water for injection, with pH 5.8-6.0.
- the formulation consists essentially of: about 180 mg/mL humanized anti-IL-6 receptor antibody, about 10 mM histidine salt buffer, about 0.5 mg/mL polysorbate-80, about 90 mM arginine hydrochloride, about 20 mg/mL sucrose, about 20 mM of methionine, water for injection, with pH 5.8-6.0.
- the formulation consists essentially of: about 180 mg/mL humanized anti-IL-6 receptor antibody, about 10 mM histidine salt buffer, about 0.5 mg/mL polysorbate-80, about 90 mM arginine hydrochloride, about 20 mg/mL sucrose, about 0.05 mM of EDTA, water for injection, with pH 5.8-6.0.
- the formulation consists essentially of: about 180 mg/mL humanized anti-IL-6 receptor antibody, about 10 mM histidine salt buffer, about 0.5 mg/mL polysorbate-80, about 90 mM arginine hydrochloride, about 20 mg/mL sucrose, about 8 mM of methionine, about 0.05 mM of EDTA, water for injection, with pH 5.8-6.0.
- the formulation consists essentially of about 180 mg/mL antibody, about 10 mM histidine salt buffer, about 0.5 mg/mL polysorbate-80, about 90 mM arginine hydrochloride, about 20 mg/mL sucrose, about 30 mM of methionine, with pH 5.6-6.4. In some embodiments, the formulation consists essentially of about 180 mg/mL antibody, about 10 mM histidine salt buffer, about 0.5 mg/mL polysorbate-80, about 120 mM arginine hydrochloride, about 20 mg/mL sucrose, about 0.05 mM of EDTA, with pH 5.6-6.4.
- the formulation has a viscosity of 8-12 cP. In some embodiments, the formulation has a viscosity of about 10 cP.
- the antibody is tocilizumab.
- the formulation is Formulation 1. In some embodiments, the formulation is Formulation 2. In some embodiments, the formulation is Formulation 3. In some embodiments, the formulation is Formulation 5. In some embodiments, the formulation is Formulation 6. In some embodiments, the formulation is Formulation 7.
- the antibody formulations of the present invention can remain stable for at least 3 months at room temperature, and remain stable after at least 3 freeze-thaw cycles.
- liquid formulations containing the monoclonal antibodies provided by the invention provide formulation combinations capable of stably storing the active ingredients.
- Table 1 shows the ingredients of Formulations 1, 2, 3, 4, 5, 6, and 7:
- the present invention provides formulation comprising a high concentration antibody for protecting monoclonal antibody, which may comprise about 120-300 mg/mL antibody, about 5-20 mM histidine salt buffer, about 0.25-1 mg/mL polysorbate-80, and a stabilizer selected from the group of about 70-200 mM arginine hydrochloride with/without combination of about 10-50 mg/mL sucrose, or about 10-50 mg/mL trehalose dihydrate, with a pH of about 5.0-7.0.
- the stabilizer further comprises methionine and/or ethylenediaminetetraacetic acid (EDTA) .
- EDTA ethylenediaminetetraacetic acid
- the stabilizer further comprises methionine.
- the stabilizer further comprises EDTA.
- the stabilizer further comprises methionine and EDTA. In some embodiments, the stabilizer further comprises 5-35 mM of methionine. In some embodiments, the formulation comprises about 180 mg/mL antibody, about 10 mM histidine salt buffer, about 0.5 mg/mL polysorbate-80, about 90 mM arginine hydrochloride, about 20 mg/mL sucrose, with pH 5.6-6.4. In some embodiments, the formulation comprises about 180 mg/mL antibody, about 10 mM sodium acetate buffer, about 0.5 mg/mL polysorbate-80, about 90 mM arginine hydrochloride, about 20 mg/mL trehalose dihydrate, with pH 5.6-6.4.
- the formulation comprises about 180 mg/mL antibody, about 10 mM sodium acetate buffer, about 0.5 mg/mL polysorbate-80, about 120 mM arginine hydrochloride, with pH 5.6-6.4. In some embodiments, the formulation comprises about 180 mg/mL antibody, about 10 mM histidine salt buffer, about 0.5 mg/mL polysorbate-80, about 90 mM arginine hydrochloride, about 20 mg/mL sucrose, about 20 mM of methionine, with pH 5.8-6.0.
- the formulation comprises about 180 mg/mL antibody, about 10 mM histidine salt buffer, about 0.5 mg/mL polysorbate-80, about 90 mM arginine hydrochloride, about 20 mg/mL sucrose, about 0.05 mM of EDTA, with pH 5.8-6.0. In some embodiments, the formulation comprises about 180 mg/mL antibody, about 10 mM histidine salt buffer, about 0.5 mg/mL polysorbate-80, about 90 mM arginine hydrochloride, about 20 mg/mL sucrose, about 8 mM of methionine, about 0.05 mM of EDTA, with pH 5.6-6.4.
- the formulation comprises about 180 mg/mL antibody, about 10 mM histidine salt buffer, about 0.5 mg/mL polysorbate-80, about 90 mM arginine hydrochloride, about 20 mg/mL sucrose, about 30 mM of methionine, with pH 5.6-6.4. In some embodiments, the formulation comprises about 180 mg/mL antibody, about 10 mM histidine salt buffer, about 0.5 mg/mL polysorbate-80, about 120 mM arginine hydrochloride, about 20 mg/mL sucrose, about 0.05 mM of EDTA, with pH 5.6-6.4.
- the formulation has a viscosity of 8-12 cP. In some embodiments, the formulation has a viscosity of about 10 cP.
- the antibody is tocilizumab.
- the “mass to volume ratio” is the ratio of the mass of the ingredients to the volume of the formulation.
- the BAT1806 antibody is a humanized anti-interleukin 6 receptor antibody prepared through antibody preparation technology.
- a CHO cell line capable of stably expressing BAT1806 was constructed, and the supernatant was collected and purified through PROTEIN A.
- the antibody formulations can be prepared by a method that comprises the steps of:
- Formulation 3 was prepared as follows:
- the above measured ingredients were dissolved in water for injection to obtain 1 L solution having 10 mM histidine buffer, 900 mM arginine hydrochloride, 200 mg/mL sucrose, and 0.5 mg/mL polysorbate-80, the sequence of adding the ingredients of the formulation does not affect the quality of the formulation, and can be flexibly selected.
- the solution prepared in (a) was then filtered through a hydrophilic polyvinylidene fluoride filter membrane of 0.22 ⁇ m pore size into an aseptic container.
- a buffer solution having 10 mM histidine buffer and a surfactant solution having 100 mg/mL polysorbate-80 were prepared by dissolving a desired amount of histidine, histidine hydrochloride or polysorbate-80 in water for injection.
- weight, weight to volume ratio, volume to volume ratio referred to herein may be converted to moles and/or molar concentrations using well-known molecular weights of the ingredients.
- weight of the ingredients may be proportionally adjusted when different formulation volumes are required. For example, 16 L, 14 L, 12 L, 10 L, 5 L of the formulation comprises 1.6, 1.4, 1.2, 1.0, 0.5 times of the cited weights, respectively.
- a sample of a formulation being tested was diluted with water to an antibody concentration of 5 mg/mL and tested by SEC-HPLC.
- the chromatographic column was TSK-GEL G3000SWXL 7.8 ⁇ 300 mM, 5 ⁇ m (TOSOH) .
- the mobile phase was 200 mM K3PO4 with 250 mM KCl (pH 7.0) .
- the UV detection wavelength was set at 280nm, the column temperature was 30 °C, the loading quantity of sample was 40 ⁇ L (200 ⁇ g protein) , and the flow was kept for 35 minutes at a rate of 0.5mL/min.
- the chromatography was recorded and after integration, the percentage of monomer and aggregate in the sample solution was calculated by area normalization method.
- a sample of a formulation being tested was diluted with water to an antibody concentration of 5mg/mL and tested by IEC-HPLC.
- Chromatographic conditions column, TSK-GEL 4.6 ⁇ 100 mM, 7 ⁇ m (TOSOH) ; mobile phase, mobile phase A (20 mM ACES, pH 8.0) and mobile phase B (20 mM ACES+200 mM NaCl, pH 8.0) ; the loading quantity of sample was 50 ⁇ g; the UV detection wavelength was 280 nm; gradient elution was performed according to the elution gradient given below for 45 minutes. The chromatography was recorded. And after integration, the percentage of the main peak, the acidic region and the basic region was respectively calculated using a peak area normalization method.
- UV spectrophotometer Eppendorf, BioPhotometer plus
- NaAc sodium acetate buffer
- Table 2 shows the types of buffer and the pH for formulations containing 180 mg/mL BAT1806, 90 mM Arg-HCl, 20 mg/mL sucrose, 0.5mg/mL polysorbate-80, and 10 mM buffer.
- SEC-HPLC monomer purity
- IEC-HPLC charge isomer
- the formulations of high concentration antibody contained 180 mg/mL antibody (BAT1806) , 90 mM Arg-HCl, 20 mg/mL sucrose, 0.5 mg/mL polysorbate-80, and 10 mM histidine salt buffer, and pH was adjusted to 5.4, 5.6, 5.8, 6.0, 6.2, 6.4 or 6.6 by HCl or NaOH.
- the viscosity of solutions containing a series of concentration antibody (102 mg/mL, 158.9 mg/mL, 181 mg/mL, 189.7 mg/mL, and 215 mg/mL) and 10 mM sodium acetate buffer at pH 5.8 were determined.
- the relationship between antibody concentration and solution viscosity is shown in Fig. 1. As can be seen from the results, the viscosity increases with the increase of antibody concentration. At the concentration of about 180 mg/mL, the viscosity is about 15 cP.
- the formulation contained high concentration antibody (BAT1806) , viscosity reducing agent (s) , 0.5 mg/mL polysorbate-80, and 20 mM histidine salt buffer, pH 5.87.
- the antibody concentration, the viscosity reducing agent (s) and the viscosity are shown in Table 7.
- Formulations 1, 2, 3, and 4 were formulated according to the method of Example 1. (Formulation 8) was manufactured by Genentech (B1095B01) .
- the protein T m (half denaturation temperature) was determined by multifunctional protein stability analysis system (UNcle, Unchained Labs) through the detection method of full spectrum of fluorescence, static light scattering and dynamic light scattering.
- the turbidity of the formulation was determined according to the method of Example 2 under the optical density (OD) 340 nm. And the viscosity of formulation was determined. The results are shown in Table 8.
- T m results show that Formulation 3 had a highest T m value, indicating that the protein would be more stable in Formulation 3. Compared with Formulation 4, even though Formulation 3 comprised an amount of sucrose and did not comprise methionine, the viscosity of Formulation 3 was the lowest and lower than that of Formulation 4. Formulations 1, 2 and 3 had lower turbidity compared with Formulation 4. The size, turbidity and viscosity of all formulations are acceptable.
- BAT1806 antibody Formulation 1 Formulation 2, Formulation 3, Formulation 4 with an antibody concentration of about 180 mg/mL were prepared as described in Example 1.
- Formulations 1, 2, 3, 4, three freeze-thaw cycles were repeated under -60 °C to 25 °C. The transparency, turbidity, SEC, IEC were observed.
- the turbidity was measured as described in Example 4. The results are shown in Table 9. The turbidity of Formulation 4 had an increasing tend with the increase of freeze-thaw cycles, while the turbidities of other formulations did not increase.
- Formulations 1, 2, 3, 4, 5, 6 and 8 were placed in a biochemical incubator for 3 months under the condition of (25 ⁇ 2) °C and sampled at the end of the 0 th (0M) , 1 st (1M) , 2 nd (2M) , 3 rd (3M) and 6 th month (6M) , respectively.
- the samples were examined with regard to monomer purity (SEC-HPLC) and charge isomer.
- Formulations 3 and 7 were placed in a biochemical incubator for 3 months under the condition of (25 ⁇ 2) °C and sampled at the end of the 0 th (0M) , 1 st (1M) , 2 nd (2M) and 3 rd month (3M) , respectively.
- the samples were examined with regard to monomer purity (SEC-HPLC) and charge isomer. The results are shown in Table 11b.
- Formulations 1, 2, 3, 4, 5, 6 and 7 were subjected to high temperature and light studies to investigate the stability of the formulations under high temperature (40 °C for 4 weeks) and light conditions (4500 ⁇ 500 Lx) .
- the test method is described in the other examples.
- the humanized anti-interleukin 6 receptor antibody BAT1806 was expressed in CHO cells.
- the expression vector containing the antibody gene was constructed by a conventional molecular biology method (molecular cloning) using a derived cell line of CHO-K1 cells (ATCC CCL61) as a host cell for expression.
- a high yield stable cell line is briefly described as follows: host cells were grown in suspension in CD-CHO medium (Gibco, CA) , the host cells in logarithmic growth phase were centrifuged, resuspended in fresh CD-CHO medium, the cells were counted and the cell density was adjusted to 1.43 ⁇ 10 7 cells/mL, 600ul of the above cell suspension was added to an electroporation cuvette, and then 40ug linearized plasmid was added, and pipetting was used to mix the cells with the plasmid uniformly. Electroshock conversion was performed using a Bio-rad electrometer with instrument parameters set as follows: capacitance: 960uFD, and voltage: 300 V. Typically the electric shock was performed for 15-20 milliseconds.
- the electrically shocked cells were immediately resuspended in 37 °C pre-heated CD-CHO medium, inoculated in a 96-well plate at 100ul per well, and 2-3 days later an equal amount of selection medium (CD-CHO media + 50 ⁇ M MSX) was added.
- the 96-well plate cell culture supernatant was analyzed to determine the level of antibody expression. Clones with higher expression levels were transferred from a 96-well plate to a 24-well plate, and after the cells were grown to a certain amount, the cells were transferred to a 6-well plate so that 2 ⁇ 10 5 cells were contained in 3 mL culture medium per well, and the antibody yield and yield of the cells were measured. 20-30 clones were transferred to shake flasks for further evaluation.
- the final 5-8 clones with the highest expression were subcloned and further tested for expression.
- the culture fluid was harvested, the cells were separated from the culture medium by low-speed centrifugation, and the supernatant of the centrifugation was further clarified by high-speed centrifugation. Affinity purification with protein A and ion exchange purification were performed.
Abstract
A liquid formulation comprises high concentrations humanized antibodies for treating an IL-6-related disease. The antibody formulation provides good antibody stability, acceptable viscosity for subcutaneous injection, prevents aggregation and degradation of the monoclonal antibody, and acidic isomer increase. The formulation is applicable in stabilizing the structure and function of the humanized antibody.
Description
The invention relates to liquid formulations of high concentrations of humanized anti-interleukin 6 receptor (IL-6R) antibodies for treating interleukin 6 (IL-6) related diseases.
Background Art
Humanized anti-interleukin 6 receptor antibodies are useful for the treatment of rheumatoid arthritis (RA) [Josef S Smolen, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update, Ann Rheum Dis, 2014; 73 (3) : 492–509] whose mechanisms are binding soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R) and inhibiting sIL-6R and mIL-6R mediated signaling.
Pharmaceutical antibodies are typically administered by injection. Subcutaneous injections allow faster administration as compared with intravenous injections, and self-injection by patients. However, for antibodies that require a high dosage (e.g., over 100 mg per dose) , the antibody concentration in a subcutaneous formulation needs to be high due to the limited volume that can be administered by each subcutaneous injection, which presents formulation challenges. For example, due to high concentration, antibodies tend to aggregate which leads to reduced stability and shorter self-life. High concentration also increases the viscosity of the formulation which can make manufacturing and injection through a needle difficult. To increase shelf-life, formulations can be prepared as powders by the lyophilization. However, lyophilized powder requires reconstitution in water, making administration more complicated. Therefore, there is a need for high concentration antibody liquid formulations having long term stability and suitable for subcutaneous injection that do not require reconstitution.
Summary
It is an objective of the present invention to provide a stable liquid formulation comprising a high concentration of monoclonal antibodies that is suitable for subcutaneous injection.
The objective of the present invention is achieved by the following technical means:
In one aspect, the invention provides an antibody formulation comprising a high concentration of a humanized anti-interleukin 6 receptor antibody, a buffer system, a stabilizer and a surfactant. Specifically, the antibody formulation of present invention comprises, consists essentially of, or consists of the following ingredients:
(1) 120-300 mg/mL humanized anti-IL-6 receptor antibody;
(2) a buffer system comprising 5-30 mM histidine and a salt thereof or 5-30 mM acetic acid and a salt thereof;
(3) 0.1-1.0 mg/mL of a surfactant;
(4) 70-200 mM of a stabilizer;
(5) water for injection.
The pH of the antibody formulation is 5.0-7.0.
In some embodiments, a formulation comprises a humanized PM-1 antibody described in US2005/0142635, and optionally one or more of its variants, such as those descripted in US2016/0152714. In some embodiments, the humanized anti-interleukin 6 receptor antibody is tocilizumab (
or
or a biosimilar thereof, such as BAT1806 (BIIB800) ) . In some embodiments, tocilizumab comprises an antibody comprising a heavy chain shown in SEQ ID NO. 1 and a light chain shown in SEQ ID NO. 2. SEQ ID NO. 1 is shown in Table A and SEQ ID NO. 2 is shown in Table B. In some embodiments, tocilizumab comprises an antibody comprising two heavy chains, each shown in SEQ ID NO. 1 and two light chains, each shown in SEQ ID NO. 2. In some embodiments, tocilizumab further comprises one or more variants of the antibody comprising a heavy chain shown in SEQ ID NO. 1 and a light chain shown in SEQ ID NO. 2, such as those descripted in US2016/0152714. In some embodiments, the humanized anti-interleukin 6 receptor antibody is expressed in CHO cells by genetic engineering methods and purified by a series of standard chromatographic steps. After the antibody is prepared, a pharmaceutical formulation is prepared. Each of US2005/0142635 and US2016/0152714 is hereby incorporated by reference in its entirety.
Table A. Heavy Chain Amino Acid Sequence of BAT1806 (BIIB800)
Table B. Light Chain Amino Acid Sequence of BAT1806 (BIIB800)
In some embodiments, the concentration of the humanized anti-IL-6 receptor antibody in the formulation is 130-280 mg/mL. In some embodiments, the concentration of the humanized anti-IL-6 receptor antibody in the formulation is 140-250 mg/mL. In some embodiments, the concentration of the humanized anti-IL-6 receptor antibody in the formulation is 160-200 mg/mL. In some embodiments, the concentration of the humanized anti-IL-6 receptor antibody in the formulation is 180 mg/mL.
In some embodiments, the stabilizer is selected from arginine or a salt thereof (e.g., arginine hydrochloride) or a combination of arginine or a salt thereof and sucrose, or trehalose (which may be added as a hydrate) . In some embodiments, the stabilizer is a combination of 70-200 mM of arginine and/or a salt thereof (e.g., 14.746-42.132 mg/mL of arginine hydrochloride) and 29-87 mM (10-30 mg/mL) sucrose; or the stabilizer is a combination of 70-200 mM of arginine and/or a salt thereof (e.g., 14.746-42.132 mg/mL of arginine hydrochloride) and 26-79 mM trehalose (e.g., 10-30 mg/mL trehalose dihydrate) ; or the stabilizer is 70-200 mM of arginine and/or a salt thereof (e.g, 14.746-42.132 mg/mL arginine hydrochloride) . In some embodiments, the stabilizer is a combination of 80-100 mM of arginine and/or a salt thereof (e.g., 16.853-21.066 mg/mL of arginine hydrochloride) and 44-73 mM (15-25 mg/mL) sucrose; or the stabilizer is a combination of 80-100 mM of arginine and/or a salt thereof (e.g., 16.853-21.066 mg/mL of arginine hydrochloride) and 40-66 mM trehalose (e.g., 15-25 mg/mL trehalose dihydrate) ; or the stabilizer is 110-130 mM of arginine and/or a salt thereof (e.g, 23.173-27.386 mg/mL arginine hydrochloride) . In some embodiments, the stabilizer is a combination of about 90 mM of arginine and/or a salt thereof (e.g., about 18.959 mg/mL of arginine hydrochloride) and about 58.4 mM (about 20 mg/mL) sucrose; or the stabilizer is a combination of about 90 mM of arginine and/or a salt thereof (e.g., about 18.959 mg/mL of arginine hydrochloride) and about 52.9 mM trehalose (e.g., about 20 mg/mL trehalose dihydrate) ; or the stabilizer is about 120 mM of arginine and/or a salt thereof (e.g, about 25.279 mg/mL arginine hydrochloride) . In some embodiments, the stabilizer further comprises methionine and/or ethylenediaminetetraacetic acid (EDTA) . In some embodiments, the stabilizer further comprises methionine. In some embodiments, the stabilizer further comprises EDTA. In some embodiments, the stabilizer further comprises methionine and EDTA. In some embodiments, the stabilizer further comprises 5-35 mM of methionine. In some embodiments, the stabilizer further comprises 5-30 mM of methionine. In some embodiments, the stabilizer further comprises 5 mM, 8 mM, 10 mM, 15 mM, 20 mM, 25 mM, 30 mM, or 35 mM of methionine. In some embodiments, the stabilizer further comprises 5-15 mM of methionine. In some embodiments, the stabilizer further comprises 0.01-0.1 mM of EDTA. In some embodiments, the stabilizer further comprises 0.02-0.07 mM of EDTA. In some embodiments, the stabilizer further comprises 0.02 mM, 0.03 mM, 0.04 mM, 0.05 mM, 0.06 mM, or 0.07 mM of EDTA. In some embodiments, the stabilizer further comprises 5 mM, 8 mM, 10 mM, 15 mM, 20 mM, 25 mM, or 30 mM of methionine and also comprises 0.02 mM, 0.03 mM, 0.04 mM, 0.05 mM, 0.06 mM, 0.07 mM, 0.08 mM, 0.09 mM, or 0.1 mM of EDTA. In some embodiments, the stabilizer further comprises 5-20 mM of methionine and 0.02-0.1 mM of EDTA. In some embodiments, the stabilizer further comprises 8 mM of methionine and 0.05 mM of EDTA. Unless specified otherwise, methionine as used herein includes one or more of its salts or a mixture thereof, and EDTA as used herein includes one of more of its salts or a mixture thereof.
In some embodiments, the stabilizer further comprises between about 5 mM and about 35 mM of methionine. In some embodiments, the stabilizer further comprises about 5 mM, about 8 mM, about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM or about 35 mM of methionine. In some embodiments, the stabilizer further comprises between about 0.01 mM and about 0.1 mM of EDTA. In some embodiments, the stabilizer further comprises between about 0.02 mM and about 0.07 mM of EDTA. In some embodiments, the stabilizer further comprises about 0.02 mM, about 0.03 mM, about 0.04 mM, about 0.05 mM, about 0.06 mM, about 0.07 mM, about 0.08 mM, about 0.09 mM, or about 0.1 mM of EDTA. In some embodiments, the stabilizer further comprises between about 5 mM and about 20 mM of methionine and between about 0.02 mM and about 0.1 mM of EDTA. In some embodiments, the stabilizer further comprises about 5 mM, about 8 mM, about 10 mM, about 15 mM, about 20 mM, about 25 mM, or about 30 mM of methionine and also comprises about 0.02 mM, about 0.03 mM, about 0.04 mM, about 0.05 mM, about 0.06 mM, about 0.07 mM, about 0.08 mM, about 0.09 mM, or about 0.1 mM of EDTA. In some embodiments, the stabilizer further comprises about 8 mM of methionine and about 0.05 mM of EDTA.
In some embodiments, the surfactant is polysorbate-80. In some embodiments, the surfactant is 0.1-0.7 mg/mL polysorbate-80. In some embodiments, the surfactant is 0.45-0.55 mg/mL polysorbate-80. In some embodiments, the surfactant is about 0.5 mg/mL polysorbate-80.
In some embodiments, the buffer system comprises 5-20 mM histidine and a salt thereof or 5-20 mM acetic acid and a salt thereof. In some embodiments, the buffer system comprises 8-15 mM histidine and a salt thereof or 8-15 mM acetic acid and a salt thereof. In some embodiments, the buffer system comprises 10 mM histidine and a salt thereof. In some embodiments, the buffer system comprises 10 mM acetic acid and a salt thereof.
In some embodiments, the pH of the antibody formulation is 5.5-6.5; or, the pH of the antibody formulation is between 5.6 and 6.4; or, the pH of the antibody formulation is between 5.8 and 6.2; or, the pH of the antibody formulation is between 5.8 and 6.0; or, the pH of the antibody formulation is between 6.0 and 6.2; or, the pH of the antibody formulation is about 5.8.
In some embodiments, the antibody formulation has a viscosity of from 0 to 20 cP. In some embodiments, the antibody formulation has a viscosity of from 5 cP to 15 cP. In some embodiments, the antibody formulation has a viscosity of from 8 cP to 12 cP. In some embodiments, the antibody formulation has a viscosity of about 10 cP.
In some embodiments, the antibody formulation comprises, consists essentially of, or consists of:
(1) 160-200 mg/mL humanized anti-IL-6 receptor antibody;
(2) 8-15 mM histidine salt buffer;
(3) 0.45 mg/mL to 0.65 mg/mL polysorbate-80;
(4) 80-100 mM arginine hydrochloride;
(5) 15-25 mg/mL sucrose;
(6) water for injection;
the pH is 5.6-6.4.
In some embodiments, the formulation comprises, consists essentially of, or consists of:
(1) 160-200 mg/mL humanized anti-IL-6 receptor antibody;
(2) 8-15 mM sodium acetate buffer;
(3) 0.45-0.65 mg/mL polysorbate-80;
(4) 80-100 mM arginine hydrochloride;
(5) 40-66 mM trehalose (e.g., 15-25 mg/mL trehalose dihydrate) ;
(6) water for injection;
the pH is 5.6-6.4.
In some embodiments, the formulation comprises, consists essentially of, or consists of:
(1) 160-200 mg/mL humanized anti-IL-6 receptor antibody;
(2) 8-15 mM sodium acetate buffer;
(3) 0.45-0.65 mg/mL polysorbate-80;
(4) 110-130 mM arginine hydrochloride;
(5) water for injection;
the pH is 5.6-6.4.
In some embodiments, the antibody formulation comprises, consists essentially of, or consists of:
(1) 160-200 mg/mL humanized anti-IL-6 receptor antibody;
(2) 8-15 mM histidine salt buffer;
(3) 0.45 mg/mL to 0.65 mg/mL polysorbate-80;
(4) 80-100 mM arginine hydrochloride;
(5) 15-25 mg/mL sucrose;
(6) 15-35 mM of methionine;
(7) water for injection;
the pH is 5.6-6.4.
In some embodiments, the antibody formulation comprises, consists essentially of, or consists of:
(1) 160-200 mg/mL humanized anti-IL-6 receptor antibody;
(2) 8-15 mM histidine salt buffer;
(3) 0.45 mg/mL to 0.65 mg/mL polysorbate-80;
(4) 80-100 mM arginine hydrochloride;
(5) 15-25 mg/mL sucrose;
(6) 15-25 mM of methionine;
(7) water for injection;
the pH is 5.6-6.4.
In some embodiments, the antibody formulation comprises, consists essentially of, or consists of:
(1) 160-200 mg/mL humanized anti-IL-6 receptor antibody;
(2) 8-15 mM histidine salt buffer;
(3) 0.45 mg/mL to 0.65 mg/mL polysorbate-80;
(4) 80-150 mM arginine hydrochloride;
(5) 15-25 mg/mL sucrose;
(6) 0.02-0.1 mM of EDTA;
(7) water for injection;
the pH is 5.6-6.4.
In some embodiments, the antibody formulation comprises, consists essentially of, or consists of:
(1) 160-200 mg/mL humanized anti-IL-6 receptor antibody;
(2) 8-15 mM histidine salt buffer;
(3) 0.45 mg/mL to 0.65 mg/mL polysorbate-80;
(4) 80-100 mM arginine hydrochloride;
(5) 15-25 mg/mL sucrose;
(6) 0.02-0.1 mM of EDTA;
(7) water for injection;
the pH is 5.6-6.4.
In some embodiments, the antibody formulation comprises, consists essentially of, or consists of:
(1) 160-200 mg/mL humanized anti-IL-6 receptor antibody;
(2) 8-15 mM histidine salt buffer;
(3) 0.45 mg/mL to 0.65 mg/mL polysorbate-80;
(4) 80-100 mM arginine hydrochloride;
(5) 15-25 mg/mL sucrose;
(6) 5-10 mM of methionine;
(7) 0.02-0.1 mM of EDTA;
(8) water for injection;
the pH is 5.6-6.4.
In some embodiments, the formulation comprises, consists essentially of, or consists of:
(1) 180 mg/mL humanized anti-IL-6 receptor antibody;
(2) 10 mM histidine salt buffer;
(3) 0.5 mg/mL polysorbate-80;
(4) 90 mM arginine hydrochloride;
(5) 20 mg/mL sucrose;
(6) water for injection;
the pH is about 5.6-6.4.
In some embodiments, the formulation comprises, consists essentially of, or consists of:
(1) 180 mg/mL humanized anti-IL-6 receptor antibody;
(2) 10 mM sodium acetate buffer;
(3) 0.5 mg/mL polysorbate-80;
(4) 90 mM arginine hydrochloride;
(5) 52.9 mM trehalose (e.g., 20 mg/mL trehalose dihydrate) ;
(6) water for injection;
the pH is about 5.6-6.4.
In some embodiments, the formulation comprises, consists essentially of, or consists of:
(1) 180 mg/mL humanized anti-IL-6 receptor antibody;
(2) 10 mM sodium acetate buffer;
(3) 0.5 mg/mL polysorbate-80;
(4) 120 mM arginine hydrochloride;
(5) water for injection;
the pH is about 5.6-6.4.
In some embodiments, the antibody formulation comprises, consists essentially of, or consists of:
(1) 180 mg/mL humanized anti-IL-6 receptor antibody;
(2) 10 mM histidine salt buffer;
(3) 0.5 mg/mL polysorbate-80;
(4) 90 mM arginine hydrochloride;
(5) 20 mg/mL sucrose;
(6) 20 mM of methionine;
(7) water for injection;
the pH is 5.6-6.4.
In some embodiments, the antibody formulation comprises, consists essentially of, or consists of:
(1) 180 mg/mL humanized anti-IL-6 receptor antibody;
(2) 10 mM histidine salt buffer;
(3) 0.5 mg/mL polysorbate-80;
(4) 90 mM arginine hydrochloride;
(5) 20 mg/mL sucrose;
(6) 30 mM of methionine;
(7) water for injection;
the pH is 5.6-6.4.
In some embodiments, the antibody formulation comprises, consists essentially of, or consists of:
(1) 180 mg/mL humanized anti-IL-6 receptor antibody;
(2) 10 mM histidine salt buffer;
(3) 0.5 mg/mL polysorbate-80;
(4) 90 mM arginine hydrochloride;
(5) 20 mg/mL sucrose;
(6) 0.05 mM of EDTA;
(7) water for injection;
the pH is 5.6-6.4.
In some embodiments, the antibody formulation comprises, consists essentially of, or consists of:
(1) 180 mg/mL humanized anti-IL-6 receptor antibody;
(2) 10 mM histidine salt buffer;
(3) 0.5 mg/mL polysorbate-80;
(4) 120 mM arginine hydrochloride;
(5) 20 mg/mL sucrose;
(6) 0.05 mM of EDTA;
(7) water for injection;
the pH is 5.6-6.4.
In some embodiments, the antibody formulation comprises, consists essentially of, or consists of:
(1) 180 mg/mL humanized anti-IL-6 receptor antibody;
(2) 10 mM histidine salt buffer;
(3) 0.5 mg/mL polysorbate-80;
(4) 90 mM arginine hydrochloride;
(5) 20 mg/mL sucrose;
(6) 8 mM of methionine;
(7) 0.05 mM of EDTA;
(8) water for injection;
the pH is 5.6-6.4.
In some embodiments, the pH of the antibody formulation is about 5.8. In some embodiments, the pH of the antibody formulation is about 6.
In some embodiments, the viscosity of the antibody formulation is 5 cP to 15 cP. In some embodiments, the viscosity of the antibody formulation is 8 cP to 12 cP. In some embodiments, the viscosity of the antibody formulation is about 10 cP.
In some embodiments, a base is added to the antibody formulation for adjusting the pH. In an exemplary embodiment, the base is NaOH.
The antibody formulation is an aqueous formulation for injection. The formulation is suitable for subcutaneous injection.
In another aspect, the invention also provides a method to prepare the antibody formulation, comprising the steps of:
(1) dissolving the buffer, stabilizer and surfactant in water for injection to form a high concentration stabilizer solution having the desired concentrations of the buffer and surfactant and a high concentration of the stabilizer;
(2) adding the surfactant into a buffered antibody solution comprising a high concentration of the antibody and the desired concentration of the buffer to form an antibody surfactant solution;
(3) mixing the high concentration stabilizer solution prepared in the step (1) with the antibody surfactant solution prepared in the step (2) to provide the formulation.
In some embodiments, the pH of the solution prepared in the step (1) is adjusting with an aqueous sodium hydroxide solution.
In some embodiments, the method further comprises filtering the solution prepared in step (1) through a filter membrane into an aseptic container before adding to the antibody solution. In some embodiments, the pore size of the filter membrane is 0.22 μm for filtering bacteria and fungi. In some embodiments, in step (2) , the surfactant is added to the buffered antibody solution as a surfactant solution.
The formulations disclosed herein are prepared without lyophilization.
The antibody formulation is a pharmaceutical formulation for treating IL-6 related diseases. In some embodiments, provided is a method for treating IL-6 related diseases comprising administering an effective amount of a formulation described herein to a patient in need thereof. In some embodiments, provided is use of a formulation described herein in the preparation of a medicament for treating IL-6 related diseases. In some embodiments, provided is use of a formulation described herein for treating IL-6 related diseases. In some embodiments, the IL-6 related diseases include: adult rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, giant lymph node hyperplasia, cytokine storm caused by immunotherapy, cytokine release syndrome, adult Still's disease, recurrent polychondritis, type II diabetes, ankylosing spondylitis, thyroid-associated ocular diseases, cardiovascular diseases caused by rheumatoid arthritis, polymyalgia rheumatica, acute graft-versus-host disease, non-ST-segment elevation myocardial infarction, systemic lupus erythematosus, schizophrenia, uveitis, ovarian cancer, anti-neutrophil cytoplasmic antibody-associated vasculitis, neuromyelitis optica, chronic glomerulonephritis, colorectal cancer and the like. In some embodiments, the IL-6 related disease is selected from rheumatoid arthritis, cytokine release syndrome, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, and giant lymph node hyperplasia. In some embodiments, the effective amount of the formulation is an amount that comprises 120-300 mg per dose of the antibody once every 1 to 3 weeks.
The antibody formulations provided by the invention comprise a high concentration of antibody with an acceptable viscosity, low turbidity and high stability suitable for administering high doses of the antibody by subcutaneous injections. The antibody formulations have been developed to remarkably inhibit the formation of acidic peaks, dimers, aggregates, degradants and insoluble microparticles during freezing/thawing cycles, long-term storage and temperature variation processes. In particular, the humanized anti-interleukin 6 receptor antibodies remain stable in the above formulations after at least 3 freeze-thaw cycles, stable at room temperature for at least 3 months. Therefore, the antibody formulations of the present invention can be used for stably storing the humanized anti-interleukin 6 receptor antibody for treating IL-6-related diseases by subcutaneous injections of the antibody in high doses required for treatment.
Figure 1. The relationship between antibody concentration and solution viscosity.
The present invention provides antibody formulations by selecting buffer solutions and stabilizers, to enhance the stability of the high concentration humanized anti-interleukin 6 receptor antibody formulation, and prevent monoclonal antibody aggregation, degradation and acidic isomer increase, while having low turbidity and viscosity acceptable for subcutaneous injection.
The term “about” when used before a numerical value indicates that the value may vary within a reasonable range, such as within ±10%, ±5%or ±1%of the stated value, and include the stated value.
As used herein, the term “comprising” is intended to mean that the compositions or methods, etc., include the recited elements, but do not exclude others. “Consisting essentially of” when used to define compositions or methods, shall mean excluding other elements of any essential significance to the combination for the intended use, but not excluding elements that do not materially affect the characteristic (s) of the compositions or methods. “Consisting of” shall mean excluding elements not specifically recited. Embodiments defined by each of these transition terms are within the scope of this invention.
Terms as “stability” and “stable” used herein refer to the situation that in a liquid formulation comprising an antibody, the antibody does not, or only rarely, aggregate, degrade, or fragment under given production, formulation, transportation, and/or storage conditions. “Stable” formulations maintain biological activity under given production, formulation, transportation and/or storage conditions. The stability of the antibody, can be assessed by measuring the degree of aggregation, degradation or fragmentation and the like of the formulation by techniques such as SEC-HPLC, IEC-HPLC, CE-SDS, etc. In some embodiments, the main antibody peak in a stable formulation does not decrease more than 5 %after storing at room temperature for at least 3 months.
It should be noted that in the present invention, where a buffer or buffer system is included in a formulation, it is also meant that the buffer is included in the formulation and the buffer system is formed in the formulation by the buffer. A buffer is typically a combination of a weak acid or a weak base and its salt. For example, a histidine buffer (also called a histidine salt buffer) is typically formed by histidine and one or more of its salts, such as histidine hydrochloride, an acetate buffer is typically formed by acetic acid and one or more of its salts, such as sodium acetate. Unless otherwise specified, regardless of whether the buffer is in the form of acid and/or salt, the molar concentration of the buffer includes both the free acid/base and the salts.
In one embodiment of the invention, the concentration of the monoclonal antibody in the antibody formulation is about 120-300 mg/mL. In some embodiments, the concentration of the monoclonal antibody in the antibody formulation is about 130-280 mg/mL. In some embodiments, the concentration of the monoclonal antibody in the antibody formulation is about 140-250 mg/mL. In some embodiments, the concentration of the monoclonal antibody in the antibody formulation is about 160-200 mg/mL. In some embodiments, the concentration of the monoclonal antibody in the antibody formulation is about 180 mg/mL. In some embodiments, the buffer system is selected from histidine (His) buffer, citrate (CB) buffer, sodium acetate (NaAC) buffer, and succinic acid (Sua) buffer. In some embodiments, the buffer system is histidine buffer. In some embodiments, buffer system is sodium acetate buffer.
In some embodiments, the stabilizer comprises arginine hydrochloride, proline, lysine hydrochloride, glycine, histidine, or sodium glutamate. In some embodiments, the stabilizer comprises methionine and/or EDTA. The addition of the stabilizers further decreases the viscosity of the formulation. In some embodiments, the stabilizer is arginine hydrochloride.
In some embodiments, the surfactant is polysorbate-80.
Preferred formulations were selected by selecting buffers and viscosity reducing agents. In some embodiments, the formulation consists essentially of: about 180 mg/mL humanized anti-IL-6 receptor antibody, about 10 mM histidine salt buffer, about 0.5 mg/mL polysorbate-80, about 90 mM arginine hydrochloride, about 20 mg/mL sucrose, water for injection, with pH 5.8-6.0. In some embodiments, the formulation consists essentially of: about 180 mg/mL humanized anti-IL-6 receptor antibody, about 10 mM sodium acetate buffer solution, about 0.5 mg/mL polysorbate-80, about 90 mM arginine hydrochloride, about 20 mg/mL trehalose dihydrate, water for injection, with pH 5.8-6.0. In some embodiments, the formulation consists essentially of: about 180 mg/mL humanized anti-IL-6 receptor antibody, about 10 mM sodium acetate buffer solution, about 0.5 mg/mL polysorbate-80, about 120 mM arginine hydrochloride, water for injection, with pH 5.8-6.0. In some embodiments, the formulation consists essentially of: about 180 mg/mL humanized anti-IL-6 receptor antibody, about 10 mM histidine salt buffer, about 0.5 mg/mL polysorbate-80, about 90 mM arginine hydrochloride, about 20 mg/mL sucrose, about 20 mM of methionine, water for injection, with pH 5.8-6.0. In some embodiments, the formulation consists essentially of: about 180 mg/mL humanized anti-IL-6 receptor antibody, about 10 mM histidine salt buffer, about 0.5 mg/mL polysorbate-80, about 90 mM arginine hydrochloride, about 20 mg/mL sucrose, about 0.05 mM of EDTA, water for injection, with pH 5.8-6.0. In some embodiments, the formulation consists essentially of: about 180 mg/mL humanized anti-IL-6 receptor antibody, about 10 mM histidine salt buffer, about 0.5 mg/mL polysorbate-80, about 90 mM arginine hydrochloride, about 20 mg/mL sucrose, about 8 mM of methionine, about 0.05 mM of EDTA, water for injection, with pH 5.8-6.0. In some embodiments, the formulation consists essentially of about 180 mg/mL antibody, about 10 mM histidine salt buffer, about 0.5 mg/mL polysorbate-80, about 90 mM arginine hydrochloride, about 20 mg/mL sucrose, about 30 mM of methionine, with pH 5.6-6.4. In some embodiments, the formulation consists essentially of about 180 mg/mL antibody, about 10 mM histidine salt buffer, about 0.5 mg/mL polysorbate-80, about 120 mM arginine hydrochloride, about 20 mg/mL sucrose, about 0.05 mM of EDTA, with pH 5.6-6.4.
In some embodiments, the formulation has a viscosity of 8-12 cP. In some embodiments, the formulation has a viscosity of about 10 cP.
In some embodiments, the antibody is tocilizumab.
In some embodiments, the formulation is Formulation 1. In some embodiments, the formulation is Formulation 2. In some embodiments, the formulation is Formulation 3. In some embodiments, the formulation is Formulation 5. In some embodiments, the formulation is Formulation 6. In some embodiments, the formulation is Formulation 7.
According to the evaluation of the stability of the above formulations, the antibody formulations of the present invention can remain stable for at least 3 months at room temperature, and remain stable after at least 3 freeze-thaw cycles.
The liquid formulations containing the monoclonal antibodies provided by the invention provide formulation combinations capable of stably storing the active ingredients.
Table 1 shows the ingredients of Formulations 1, 2, 3, 4, 5, 6, and 7:
Table 1. Formulation Ingredient List
The present invention provides formulation comprising a high concentration antibody for protecting monoclonal antibody, which may comprise about 120-300 mg/mL antibody, about 5-20 mM histidine salt buffer, about 0.25-1 mg/mL polysorbate-80, and a stabilizer selected from the group of about 70-200 mM arginine hydrochloride with/without combination of about 10-50 mg/mL sucrose, or about 10-50 mg/mL trehalose dihydrate, with a pH of about 5.0-7.0. In some embodiments, the stabilizer further comprises methionine and/or ethylenediaminetetraacetic acid (EDTA) . In some embodiments, the stabilizer further comprises methionine. In some embodiments, the stabilizer further comprises EDTA. In some embodiments, the stabilizer further comprises methionine and EDTA. In some embodiments, the stabilizer further comprises 5-35 mM of methionine. In some embodiments, the formulation comprises about 180 mg/mL antibody, about 10 mM histidine salt buffer, about 0.5 mg/mL polysorbate-80, about 90 mM arginine hydrochloride, about 20 mg/mL sucrose, with pH 5.6-6.4. In some embodiments, the formulation comprises about 180 mg/mL antibody, about 10 mM sodium acetate buffer, about 0.5 mg/mL polysorbate-80, about 90 mM arginine hydrochloride, about 20 mg/mL trehalose dihydrate, with pH 5.6-6.4. In some embodiments, the formulation comprises about 180 mg/mL antibody, about 10 mM sodium acetate buffer, about 0.5 mg/mL polysorbate-80, about 120 mM arginine hydrochloride, with pH 5.6-6.4. In some embodiments, the formulation comprises about 180 mg/mL antibody, about 10 mM histidine salt buffer, about 0.5 mg/mL polysorbate-80, about 90 mM arginine hydrochloride, about 20 mg/mL sucrose, about 20 mM of methionine, with pH 5.8-6.0. In some embodiments, the formulation comprises about 180 mg/mL antibody, about 10 mM histidine salt buffer, about 0.5 mg/mL polysorbate-80, about 90 mM arginine hydrochloride, about 20 mg/mL sucrose, about 0.05 mM of EDTA, with pH 5.8-6.0. In some embodiments, the formulation comprises about 180 mg/mL antibody, about 10 mM histidine salt buffer, about 0.5 mg/mL polysorbate-80, about 90 mM arginine hydrochloride, about 20 mg/mL sucrose, about 8 mM of methionine, about 0.05 mM of EDTA, with pH 5.6-6.4. In some embodiments, the formulation comprises about 180 mg/mL antibody, about 10 mM histidine salt buffer, about 0.5 mg/mL polysorbate-80, about 90 mM arginine hydrochloride, about 20 mg/mL sucrose, about 30 mM of methionine, with pH 5.6-6.4. In some embodiments, the formulation comprises about 180 mg/mL antibody, about 10 mM histidine salt buffer, about 0.5 mg/mL polysorbate-80, about 120 mM arginine hydrochloride, about 20 mg/mL sucrose, about 0.05 mM of EDTA, with pH 5.6-6.4.
In some embodiments, the formulation has a viscosity of 8-12 cP. In some embodiments, the formulation has a viscosity of about 10 cP.
In some embodiments, the antibody is tocilizumab.
The technical solution of the present invention is further illustrated by the following specific examples, which are not intended to limit the scope of the present invention. Other non-essential modifications and adaptations of the invention according to the inventive concept are within the scope of the invention.
It should be noted that in the present invention, the “mass to volume ratio” is the ratio of the mass of the ingredients to the volume of the formulation.
Antibody Sample
The BAT1806 antibody is a humanized anti-interleukin 6 receptor antibody prepared through antibody preparation technology. A CHO cell line capable of stably expressing BAT1806 was constructed, and the supernatant was collected and purified through PROTEIN A.
Example 1. Formulation Preparation
The antibody formulations can be prepared by a method that comprises the steps of:
As an exemplary example, Formulation 3 was prepared as follows:
(a) The following amounts of ingredients were measured: 0.31 g histidine, 1.68 g histidine hydrochloride, 189.6 g arginine hydrochloride, 200 g sucrose, 0.5 g polysorbate-80.
The above measured ingredients were dissolved in water for injection to obtain 1 L solution having 10 mM histidine buffer, 900 mM arginine hydrochloride, 200 mg/mL sucrose, and 0.5 mg/mL polysorbate-80, the sequence of adding the ingredients of the formulation does not affect the quality of the formulation, and can be flexibly selected. The solution prepared in (a) was then filtered through a hydrophilic polyvinylidene fluoride filter membrane of 0.22 μm pore size into an aseptic container.
(b) A buffer solution having 10 mM histidine buffer and a surfactant solution having 100 mg/mL polysorbate-80 were prepared by dissolving a desired amount of histidine, histidine hydrochloride or polysorbate-80 in water for injection.
(c) An antibody concentrate containing a total of 1800 g antibody was thawed in a water bath (room temperature) followed by buffer exchange with the buffer solution prepared in (b) and concentrated by ultrafiltration through 30 KD polyether sulfone ultrafiltration membrane (Millipore, C9MA73422) to obtain 9L high concentration antibody solution (200 mg/mL) with histidine buffer (10 mM) .
(d) To the antibody solution obtained in (c) was added the surfactant solution (100 mg/mL polysorbate-80) prepared in (b) such that the surfactant concentration was 0.5 mg/mL.
(e) To 9 L of the antibody solution obtained in (d) was added 1 L of the solution obtained in (a) with stirring to obtain the liquid Formulation 3, which was packaged for use in vials or pre-filled syringes.
The skilled artisan will appreciate that the weight, weight to volume ratio, volume to volume ratio referred to herein may be converted to moles and/or molar concentrations using well-known molecular weights of the ingredients. The skilled artisan will also appreciate that the weight of the ingredients may be proportionally adjusted when different formulation volumes are required. For example, 16 L, 14 L, 12 L, 10 L, 5 L of the formulation comprises 1.6, 1.4, 1.2, 1.0, 0.5 times of the cited weights, respectively.
Other formulations were prepared using similar methods.
Example 2. Analytic Methods
The following methods were used to analyze the formulations disclosed herein.
SEC-HPLC analysis method:
A sample of a formulation being tested was diluted with water to an antibody concentration of 5 mg/mL and tested by SEC-HPLC. The chromatographic column was TSK-GEL G3000SWXL 7.8×300 mM, 5 μm (TOSOH) . The mobile phase was 200 mM K3PO4 with 250 mM KCl (pH 7.0) . The UV detection wavelength was set at 280nm, the column temperature was 30 ℃, the loading quantity of sample was 40 μL (200 μg protein) , and the flow was kept for 35 minutes at a rate of 0.5mL/min. The chromatography was recorded and after integration, the percentage of monomer and aggregate in the sample solution was calculated by area normalization method.
IEC-HPLC analysis method:
A sample of a formulation being tested was diluted with water to an antibody concentration of 5mg/mL and tested by IEC-HPLC. Chromatographic conditions: column, TSK-GEL
4.6×100 mM, 7 μm (TOSOH) ; mobile phase, mobile phase A (20 mM ACES, pH 8.0) and mobile phase B (20 mM ACES+200 mM NaCl, pH 8.0) ; the loading quantity of sample was 50 μg; the UV detection wavelength was 280 nm; gradient elution was performed according to the elution gradient given below for 45 minutes. The chromatography was recorded. And after integration, the percentage of the main peak, the acidic region and the basic region was respectively calculated using a peak area normalization method. (The chromatography was manually integrated, a base line was drawn at a place where the base line was relatively flat, the integration starting time and the integration ending time were about 8 minutes before and after the retention time of the main peak, vertical lines were drawn at two peak valleys around the main peak, the acidic region was before the main peak that was followed by the basic region (the main peak was followed by basic peak 1, basic peak 2 and basic peak 3 in sequence) , and a vertical line was drawn at each peak valley of the basic region. )
Elution Gradients
Viscosity Determination:
Return the sample to 25℃ normal temperature, and then measure it with a viscometer (Brookfield, DV2T) . About 1.2-1.5mL of the sample is slowly injected into the cone (to avoid bubbles) , spread evenly, and then tested on the viscometer at a temperature of 25±2℃. The torque is between 40%-70%, and the rotation is about 7-9 times for data recording.
Turbidity Determination:
Return the sample to room temperature and use an ultraviolet spectrophotometer (Eppendorf, BioPhotometer plus) for detection. Adjust the UV spectrophotometer to 340nm, calibrate it with water, and perform sample detection only when the calibration result is 0. Rinse the disposable cuvette with 300μl sample during the test, and then slowly pour the 300μl sample into the disposable cuvette to avoid air bubbles during the process, and put the cuvette into the UV spectrophotometer for data recording.
Example 3. Buffer Selection
Studies on antibody stability were performed using a variety of buffer systems.
Based on the nature of the antibody, the inventors had empirically determined a number of buffer systems:
histidine salt buffer (His)
citrate buffer (CB)
sodium acetate buffer (NaAc)
succinic acid buffer (Sua)
Table 2 shows the types of buffer and the pH for formulations containing 180 mg/mL BAT1806, 90 mM Arg-HCl, 20 mg/mL sucrose, 0.5mg/mL polysorbate-80, and 10 mM buffer.
Table 2. The Type of Buffer and the pH Value
The monomer purity (SEC-HPLC, abbreviated SEC) and charge isomer (IEC-HPLC, abbreviated IEC) of the formulations at a high temperature of 40 ℃ for 4 weeks (W) or at the condition of light (4500 ± 500 Lx) for 10 days (d) was investigated. The results are shown in Table 3 and Table 4.
Table 3. Formulation Buffer Selection at High Temperature (40 ℃)
Table 4. Formulation Buffer Selection at the condition of light (4500 ± 500 Lx)
Example 4. pH Selection
Studies on antibody stability were performed using a variety of pH value.
In this study, the formulations of high concentration antibody contained 180 mg/mL antibody (BAT1806) , 90 mM Arg-HCl, 20 mg/mL sucrose, 0.5 mg/mL polysorbate-80, and 10 mM histidine salt buffer, and pH was adjusted to 5.4, 5.6, 5.8, 6.0, 6.2, 6.4 or 6.6 by HCl or NaOH.
The monomer purity (SEC-HPLC, abbreviated SEC) and charge isomer (IEC-HPLC, abbreviated IEC) of the formulations at a high temperature 40 ℃ for 4 weeks or at a light test (4500 ± 500 Lx) for 10 days was investigated. The results are shown in Table 5 and Table 6.
Table 5. Formulation Buffer Selection at High Temperature (40 ℃)
Table 6. Formulation Buffer Selection at the condition of light (4500 ± 500 Lx)
The results of both SEC and IEC at high temperature or light condition show that the pH in the range of 5.4-6.4 could play a good buffer protection role as time went by. And the optimum pH range is 5.6-6.4. When the samples exposed to light, the lower pH of the buffer is, the better the stability of the antibody is. Considering the actual situation that the product can be stored in dark, the pH of the sample in the range of 5.4-6.4 is chosen to protect the antibody. The next experiments are carried out in the pH value 5.8.
Example 5. Viscosity Reducing Agents Selection
The viscosity of solutions containing a series of concentration antibody (102 mg/mL, 158.9 mg/mL, 181 mg/mL, 189.7 mg/mL, and 215 mg/mL) and 10 mM sodium acetate buffer at pH 5.8 were determined. The relationship between antibody concentration and solution viscosity is shown in Fig. 1. As can be seen from the results, the viscosity increases with the increase of antibody concentration. At the concentration of about 180 mg/mL, the viscosity is about 15 cP.
In this study, the formulation contained high concentration antibody (BAT1806) , viscosity reducing agent (s) , 0.5 mg/mL polysorbate-80, and 20 mM histidine salt buffer, pH 5.87. The antibody concentration, the viscosity reducing agent (s) and the viscosity are shown in Table 7.
Table 7. Viscosity results of solutions with different formulation
According to the data shown in Table 7, at 25 ℃, arginine hydrochloride and the combination of arginine hydrochloride and methionine reduced the viscosity of the solution most, followed by proline, lysine hydrochloride and glycine. In the same time, the viscosity reducing agent, arginine hydrochloride, played an important role of protecting the antibody stability. It can be described as stabilizer either.
Example 6. Formulation Characteristics
Pharmaceutical Formulations 1, 2, 3, and 4 were formulated according to the method of Example 1.
(Formulation 8) was manufactured by Genentech (B1095B01) .
The protein T
m (half denaturation temperature) was determined by multifunctional protein stability analysis system (UNcle, Unchained Labs) through the detection method of full spectrum of fluorescence, static light scattering and dynamic light scattering. The turbidity of the formulation was determined according to the method of Example 2 under the optical density (OD) 340 nm. And the viscosity of formulation was determined. The results are shown in Table 8.
Table 8. Formulation Characteristics
The T
m results show that Formulation 3 had a highest T
m value, indicating that the protein would be more stable in Formulation 3. Compared with Formulation 4, even though Formulation 3 comprised an amount of sucrose and did not comprise methionine, the viscosity of Formulation 3 was the lowest and lower than that of Formulation 4. Formulations 1, 2 and 3 had lower turbidity compared with Formulation 4. The size, turbidity and viscosity of all formulations are acceptable.
Example 7. Freeze-thaw Studies
BAT1806 antibody Formulation 1, Formulation 2, Formulation 3, Formulation 4 with an antibody concentration of about 180 mg/mL were prepared as described in Example 1. For Formulations 1, 2, 3, 4, three freeze-thaw cycles were repeated under -60 ℃ to 25 ℃. The transparency, turbidity, SEC, IEC were observed.
Transparency was observed under the light. All the formulations are clear and transparent with a slight opalescence after 0, 1 or 3 freeze-thaw cycles.
The turbidity was measured as described in Example 4. The results are shown in Table 9. The turbidity of Formulation 4 had an increasing tend with the increase of freeze-thaw cycles, while the turbidities of other formulations did not increase.
Table 9. Turbidity after Freeze-thawing
SEC and IEC were measured as described in Example 2. And the results are shown in Table 10.
Table 10. SEC and IEC after Freeze-thawing
The results showed that although the antibody formulations thawed from -60 ℃ and were subjected to three freeze-thaw cycles, the SEC and IEC were not obviously changed, indicating that the samples were stable in the repeated freeze-thaw test, no precipitate was generated, the protein did not adhere to the freeze-thaw containers.
Example 8. Stability Studies under the Acceleration Conditions
The results are shown in Table 11a.
In another experiment, Formulations 3 and 7 were placed in a biochemical incubator for 3 months under the condition of (25±2) ℃ and sampled at the end of the 0
th (0M) , 1
st (1M) , 2
nd (2M) and 3
rd month (3M) , respectively. The samples were examined with regard to monomer purity (SEC-HPLC) and charge isomer. The results are shown in Table 11b.
Table 11a. Stability under the Acceleration Conditions
Table 11b. Stability under the Acceleration Conditions
Example 9. Stability Studies under High Temperature and Light Conditions
The results under high temperature conditions are shown in Table 12.
Table 12. Test Results under High Temperature Conditions
The results under the conditions of light are shown in Table 13.
Table 13. Test Results under Light Conditions
Example 10. Stability Studies under Oscillation Condition
Experimental conditions: Formulation 1, 2, 3 and 4 were flatwise placed and oscillated at 200rpm at room temperature for 48h. The solution transparency, turbidity, SEC, IEC, were measured at regular intervals. The test methods are described with reference to other examples.
Transparency was observed under the light. All the formulations are clear and transparent with a slight opalescence after oscillation for 48 hours (h) . No visible foreign matter appeared.
The turbidity was determined as described in Example 4. The results are shown in Table 14.
Table 14. Turbidity after Oscillation for 48 hours
The SEC and IEC were determined as described in Example 2. The results are shown in Table 15.
Table 15. SEC and IEC after Oscillation for 48 hours
From the data in the table above, it can be seen that, after 48 hours of oscillation, compared with the data at 0 hour, the SEC-HPLC purity, IEC-HPLC main peak content and other test items showed no obvious change either, and the activity was within an acceptable range. Similar to the results of the freeze-thaw studies, the turbidity of Formulations 1, 2, and 3 remained low while the turbidity of Formulation 4 increased by oscillation, indicating that Formulations 1, 2, and 3 had better stability in the oscillation test than Formulation 4.
Example 11. Analytical Data for Formulation 7
Table 16. Results of Formulation 7 placed under 50℃
Table 17. Results of Formulation 7 placed under 4500±500 Lux
Example 12. Binding Studies under 25℃ Acceleration Conditions
The binding activity of Formulation 3 and 7 were tested under 25℃ accelerated conditions. The results are shown in Table 18.
Table 18. The binding activity under 25℃ accelerated conditions.
Example 13. Expression and Purification of BAT1806
With reference to the method given by Wood et al., J Immunol. 145: 3011 (1990) et al., the humanized anti-interleukin 6 receptor antibody BAT1806 was expressed in CHO cells. The expression vector containing the antibody gene was constructed by a conventional molecular biology method (molecular cloning) using a derived cell line of CHO-K1 cells (ATCC CCL61) as a host cell for expression. The construction of a high yield stable cell line is briefly described as follows: host cells were grown in suspension in CD-CHO medium (Gibco, CA) , the host cells in logarithmic growth phase were centrifuged, resuspended in fresh CD-CHO medium, the cells were counted and the cell density was adjusted to 1.43×10
7 cells/mL, 600ul of the above cell suspension was added to an electroporation cuvette, and then 40ug linearized plasmid was added, and pipetting was used to mix the cells with the plasmid uniformly. Electroshock conversion was performed using a Bio-rad electrometer with instrument parameters set as follows: capacitance: 960uFD, and voltage: 300 V. Typically the electric shock was performed for 15-20 milliseconds. The electrically shocked cells were immediately resuspended in 37 ℃ pre-heated CD-CHO medium, inoculated in a 96-well plate at 100ul per well, and 2-3 days later an equal amount of selection medium (CD-CHO media + 50 μM MSX) was added. The 96-well plate cell culture supernatant was analyzed to determine the level of antibody expression. Clones with higher expression levels were transferred from a 96-well plate to a 24-well plate, and after the cells were grown to a certain amount, the cells were transferred to a 6-well plate so that 2×10
5 cells were contained in 3 mL culture medium per well, and the antibody yield and yield of the cells were measured. 20-30 clones were transferred to shake flasks for further evaluation. The final 5-8 clones with the highest expression were subcloned and further tested for expression. The culture fluid was harvested, the cells were separated from the culture medium by low-speed centrifugation, and the supernatant of the centrifugation was further clarified by high-speed centrifugation. Affinity purification with protein A and ion exchange purification were performed.
Claims (29)
- An antibody formulation, characterized by comprising:(1) an antibody: 120-300 mg/mL humanized anti-IL-6 receptor antibody;(2) a buffer system comprising 5-30 mM histidine salt, or 5-30 mM sodium acetate;(3) a surfactant: 0.1-1.0 mg/mL;(4) a stabilizer: 70-200 mM;(5) water for injection;a pH of the antibody formulation being 5.0-7.0.
- The antibody formulation according to claim 1, wherein the concentration of the humanized anti-IL-6 receptor antibody is 160-200 mg/mL.
- The antibody formulation according to claim 1, wherein the concentration of the humanized anti-IL-6 receptor antibody is 180 mg/mL.
- The antibody formulation according to any one of claims 1 to 3, wherein the pH of the antibody formulation is 5.5-6.5.
- The antibody formulation according to any one of claims 1 to 3, wherein the pH of the antibody formulation is 5.6-6.4.
- The antibody formulation according to any one of claims 1 to 5, wherein the antibody is tocilizumab.
- The antibody formulation according to any one of claims 1 to 6 having a viscosity of from 0 to 20 cP.
- The antibody formulation according to any one of claims 1 to 7, having a viscosity of from 5 to 15 cP.
- The antibody formulation according to any one of claims 1 to 8, characterized in that, the stabilizer is selected from arginine hydrochloride, or a combination of arginine hydrochloride and sucrose, or a combination of arginine hydrochloride and trehalose dihydrate.
- The antibody formulation according to any one of claims 1 to 9, wherein the stabilizer is selected from a combination of 70-200 mM arginine hydrochloride and 10-30 mg/mL sucrose; a combination of 70-200 mM arginine hydrochloride and 10-30 mg/mL trehalose dihydrate; and 70-200 mM arginine hydrochloride.
- The antibody formulation according to any one of claims 1 to 9, wherein the stabilizer further comprises methionine and/or EDTA.
- The antibody formulation according to any one of claims 1 to 9, wherein the stabilizer further comprises 5-30 mM of methionine and/or 0.01-0.1 mM EDTA.
- The antibody formulation according to any one of claims 1 to 10, wherein the surfactant is polysorbate-80.
- The antibody formulation according to any one of claims 1 to 10, wherein the surfactant is 0.1-0.7 mg/mL polysorbate-80.
- An antibody formulation comprising:(1) 160-200 mg/mL humanized anti-IL-6 receptor antibody;(2) 8-15 mM histidine salt buffer;(3) 0.45 mg/mL to 0.65 mg/mL polysorbate-80;(4) 80-100 mM arginine hydrochloride;(5) 15-25 mg/mL sucrose;(6) 25-35 mM of methionine;(7) water for injection;with a pH of 5.6-6.4;or comprising:(1) 160-200 mg/mL humanized anti-IL-6 receptor antibody;(2) 8-15 mM histidine salt buffer;(3) 0.45 mg/mL to 0.65 mg/mL polysorbate-80;(4) 80-100 mM arginine hydrochloride;(5) 15-25 mg/mL sucrose;(6) 15-25 mM of methionine;(7) water for injection;with a pH of 5.6-6.4;or comprising:(1) 160-200 mg/mL humanized anti-IL-6 receptor antibody;(2) 8-15 mM histidine salt buffer;(3) 0.45 mg/mL to 0.65 mg/mL polysorbate-80;(4) 80-150 mM arginine hydrochloride;(5) 15-25 mg/mL sucrose;(6) 0.02-0.1 mM of EDTA;(7) water for injection;with a pH of 5.6-6.4.or comprising:(1) 160-200 mg/mL humanized anti-IL-6 receptor antibody;(2) 8-15 mM histidine salt buffer;(3) 0.45 mg/mL to 0.65 mg/mL polysorbate-80;(4) 80-100 mM arginine hydrochloride;(5) 15-25 mg/mL sucrose;(6) 0.02-0.1 mM of EDTA;(7) water for injection;with a pH of 5.6-6.4.or comprising:(1) 160-200 mg/mL humanized anti-IL-6 receptor antibody;(2) 8-15 mM histidine salt buffer;(3) 0.45 mg/mL to 0.65 mg/mL polysorbate-80;(4) 80-100 mM arginine hydrochloride;(5) 15-25 mg/mL sucrose;(6) 5-10 mM of methionine;(7) 0.02-0.1 mM of EDTA;(8) water for injection;with a pH of 5.6-6.4.
- An antibody formulation comprising:(1) 180 mg/mL humanized anti-IL-6 receptor antibody;(2) 10 mM histidine salt buffer;(3) 0.5 mg/mL polysorbate-80;(4) 90 mM arginine hydrochloride;(5) 20 mg/mL sucrose;(6) 20 mM of methionine;(7) water for injection;with a pH of 5.6-6.4;or comprising:(1) 180 mg/mL humanized anti-IL-6 receptor antibody;(2) 10 mM histidine salt buffer;(3) 0.5 mg/mL polysorbate-80;(4) 90 mM arginine hydrochloride;(5) 20 mg/mL sucrose;(6) 30 mM of methionine;(7) water for injection;with a pH of 5.6-6.4;or comprising:(1) 180 mg/mL humanized anti-IL-6 receptor antibody;(2) 10 mM histidine salt buffer;(3) 0.5 mg/mL polysorbate-80;(4) 90 mM arginine hydrochloride;(5) 20 mg/mL sucrose;(6) 0.05 mM of EDTA;(7) water for injection;with a pH of 5.6-6.4;or comprising:(1) 180 mg/mL humanized anti-IL-6 receptor antibody;(2) 10 mM histidine salt buffer;(3) 0.5 mg/mL polysorbate-80;(4) 120 mM arginine hydrochloride;(5) 20 mg/mL sucrose;(6) 0.05 mM of EDTA;(7) water for injection;with a pH of 5.6-6.4;or comprising:(1) 180 mg/mL humanized anti-IL-6 receptor antibody;(2) 10 mM histidine salt buffer;(3) 0.5 mg/mL polysorbate-80;(4) 90 mM arginine hydrochloride;(5) 20 mg/mL sucrose;(6) 8 mM of methionine;(7) 0.05 mM of EDTA;(8) water for injection;with a pH of 5.6-6.4.
- The antibody formulation according to any one of claims 1 to 16, characterized in that, the antibody formulation is a subcutaneous injection formulation.
- The antibody formulation according to any one of claims 1 to 17, characterized in that, the formulation remains stable for at least 3 months at room temperature.
- Use of the antibody formulation according to any one of claims 1 to 18 for treating IL-6 related diseases.
- The use according to claim 19, wherein the IL-6 related disease is selected from rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, giant lymph node hyperplasia, cytokine storms caused by immunotherapy, cytokine release syndrome, adult Still’s disease, recurrent polychondritis, type II diabetes, ankylosing spondylitis, thyroid-associated ophthalmopathy, cardiovascular disease caused by rheumatoid arthritis, polymyalgia rheumatica, acute graft-versus-host disease, non-ST-segment elevation myocardial infarction, systemic lupus erythematosus, schizophrenia, uveitis, ovarian cancer, anti-neutrophil cytoplasmic antibody-associated vasculitis, neuromyelitis optica, chronic glomerulonephritis, and colorectal cancer.
- The use according to claim 20, wherein the IL-6 related disease is selected from rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, cytokine release syndrome, and giant lymph node hyperplasia.
- A method to prepare the antibody formulation according to any one of claims 1 to 18, comprising the steps of:(1) dissolving the buffer, stabilizer and surfactant in water for injection to form a solution;(2) adding surfactant into an antibody solution; and(3) mixing the solution prepared in the step (1) with the antibody surfactant solution prepared in the step (2) to provide the formulation.
- A method of treating an IL-6 related disease, the method comprising administering the antibody formulation according to any one of claims 1 to 18.
- The method of claim 23, wherein the wherein the IL-6 related disease is selected from rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, giant lymph node hyperplasia, cytokine storms caused by immunotherapy, cytokine release syndrome, adult Still’s disease, recurrent polychondritis, type II diabetes, ankylosing spondylitis, thyroid-associated ophthalmopathy, cardiovascular disease caused by rheumatoid arthritis, polymyalgia rheumatica, acute graft-versus-host disease, non-ST-segment elevation myocardial infarction, systemic lupus erythematosus, schizophrenia, uveitis, ovarian cancer, anti-neutrophil cytoplasmic antibody-associated vasculitis, neuromyelitis optica, chronic glomerulonephritis, and colorectal cancer.
- The method of claim 24, wherein the IL-6 related disease is selected from rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, cytokine release syndrome, and giant lymph node hyperplasia.
- A kit comprising the antibody formulation according to any one of claims 1 to 18 contained in a container.
- The kit of claim 26, wherein the container is a single-use container or a multi-use container.
- The kit of claim 26, wherein the container is a vial, ampoule, syringe, or autoinjector.
- The kit of claim 26, wherein the container is a pre-fillable syringe (PFS) .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280054611.7A CN117858722A (en) | 2021-08-18 | 2022-08-18 | Liquid formulations comprising high concentrations of humanized antibodies for the treatment of IL-6 related diseases |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021113273 | 2021-08-18 | ||
CNPCT/CN2021/113273 | 2021-08-18 | ||
CNPCT/CN2022/077411 | 2022-02-23 | ||
CN2022077411 | 2022-02-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023020563A1 true WO2023020563A1 (en) | 2023-02-23 |
Family
ID=85240061
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/113202 WO2023020563A1 (en) | 2021-08-18 | 2022-08-18 | Liquid formulations comprising high concentrations humanized antibodies for treating il-6 related diseases |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117858722A (en) |
WO (1) | WO2023020563A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102858366A (en) * | 2010-01-20 | 2013-01-02 | 中外制药株式会社 | Solution Preparation Containing Stabilized Antibody |
CN102869346A (en) * | 2010-01-08 | 2013-01-09 | 瑞泽恩制药公司 | Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies |
WO2017155990A1 (en) * | 2016-03-07 | 2017-09-14 | Sanofi Biotechnology | Compositions and methods for treating rheumatoid arthritis |
CN109350740A (en) * | 2017-11-30 | 2019-02-19 | 百奥泰生物科技(广州)有限公司 | A kind of liquid preparation of humanized antibody that treating IL-6 related disease |
WO2022037606A1 (en) * | 2020-08-19 | 2022-02-24 | Bio-Thera Solutions, Ltd. | Liquid formulations comprising high concentrations humanized antibodies for treating il-6 related diseases |
-
2022
- 2022-08-18 WO PCT/CN2022/113202 patent/WO2023020563A1/en unknown
- 2022-08-18 CN CN202280054611.7A patent/CN117858722A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102869346A (en) * | 2010-01-08 | 2013-01-09 | 瑞泽恩制药公司 | Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies |
CN102858366A (en) * | 2010-01-20 | 2013-01-02 | 中外制药株式会社 | Solution Preparation Containing Stabilized Antibody |
WO2017155990A1 (en) * | 2016-03-07 | 2017-09-14 | Sanofi Biotechnology | Compositions and methods for treating rheumatoid arthritis |
CN109350740A (en) * | 2017-11-30 | 2019-02-19 | 百奥泰生物科技(广州)有限公司 | A kind of liquid preparation of humanized antibody that treating IL-6 related disease |
WO2019105450A1 (en) * | 2017-11-30 | 2019-06-06 | 百奥泰生物制药股份有限公司 | Liquid preparation of humanized antibody for treating il-6-related disease |
CN111110842A (en) * | 2017-11-30 | 2020-05-08 | 百奥泰生物制药股份有限公司 | Liquid preparation of humanized antibody for treating IL-6 related diseases |
WO2022037606A1 (en) * | 2020-08-19 | 2022-02-24 | Bio-Thera Solutions, Ltd. | Liquid formulations comprising high concentrations humanized antibodies for treating il-6 related diseases |
Non-Patent Citations (1)
Title |
---|
NAVAS NATALIA, HERMOSILLA JESÚS, TORRENTE-LÓPEZ ANABEL, HERNÁNDEZ-JIMÉNEZ JOSÉ, CABEZA JOSE, PÉREZ-ROBLES RAQUEL, SALMERÓN-GARCÍA : "Use of subcutaneous tocilizumab to prepare intravenous solutions for COVID-19 emergency shortage: Comparative analytical study of physicochemical quality attributes", JOURNAL OF PHARMACEUTICAL ANALYSIS, vol. 10, no. 6, 1 December 2020 (2020-12-01), pages 532 - 545, XP093036187, ISSN: 2095-1779, DOI: 10.1016/j.jpha.2020.06.003 * |
Also Published As
Publication number | Publication date |
---|---|
CN117858722A (en) | 2024-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230190649A1 (en) | Liquid formulation of humanized antibody for treating il-6-mediated diseases | |
EP3606504B1 (en) | Stable antibody formulation | |
EP2946765B1 (en) | Liquid pharmaceutical composition | |
DK2531218T3 (en) | immunoglobulin | |
EP2699265A1 (en) | STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc | |
EA028520B1 (en) | Etanercept formulations stabilized with meglumine | |
CN110494164B (en) | Human antibody preparation for targeted therapy of TNF-alpha related diseases | |
WO2022037606A1 (en) | Liquid formulations comprising high concentrations humanized antibodies for treating il-6 related diseases | |
CN113840622A (en) | Stable secukinumab injection and preparation method thereof | |
WO2023020563A1 (en) | Liquid formulations comprising high concentrations humanized antibodies for treating il-6 related diseases | |
CN114286690A (en) | Stable low viscosity antibody formulations and uses thereof | |
KR101704378B1 (en) | Composition for Stabilizing Protein and Pharmaceutical Formulation Comprising the Same | |
CN109498565B (en) | Stable anti-PD-1 antibody preparation and application thereof | |
CN114984207B (en) | anti-PD-1 nano antibody preparation | |
CN115803055A (en) | anti-PD-1 monoclonal antibody liquid preparation | |
CN110302377B (en) | Human antibody preparation for targeted therapy of TNF- α related diseases | |
US20230312734A1 (en) | Stable pharmaceutical formulation, vial, cartridge, pre-filled syringe and auto-injector comprising the same | |
WO2022217021A1 (en) | Performance-enhancing excipients and methods of reducing viscosity and increasing stability of biologic formulations | |
JP2024510480A (en) | Novel formulation of fusion protein | |
KR20230032347A (en) | Stable pharmaceutical formulation | |
WO2024023843A1 (en) | A pharmaceutical formulation of a therapeuticantibody and preparations thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22857874 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |